Adverse effects of neuromuscular blocking agents based on yellow card reporting in the U.K.: are there differences between males and females?

2006 ◽  
Vol 15 (3) ◽  
pp. 151-160 ◽  
Author(s):  
Karen Patricia Light ◽  
Anthony Timothy Lovell ◽  
Hisham Butt ◽  
Nicholas John Fauvel ◽  
Anita Holdcroft
Keyword(s):  
Adverse Effects ◽  
Neuromuscular Blocking ◽  
Neuromuscular Blocking Agents ◽  
Yellow Card ◽  
Blocking Agents ◽  
Males And Females ◽  
Card Reporting

Comparison of Two Muscle Relaxants for Tracheal Intubation in Patients Undergoing Surgery at Goa Medical College and Hospital

2021 ◽  
Vol 8 (33) ◽  
pp. 3116-3122
Author(s):  
Anisha Deulker ◽  
Rohini Bhat Pai ◽  
Shaila Kamat ◽  
Eufemia Dias
Keyword(s):  
Adverse Effects ◽  
Onset Time ◽  
Neuromuscular Blocking ◽  
Muscle Relaxants ◽  
Neuromuscular Blocking Agents ◽  
P Value ◽  
Blocking Agents ◽  
Intubating Conditions ◽  
Anaphylactoid Reactions ◽  
The Difference

BACKGROUND Cisatracurium and atracurium are intermediate acting muscle relaxants which do not depend on renal or hepatic metabolism for elimination since they undergo Hofmann elimination. Despite the advantages of cisatracurium such as minimal effects on the cardiovascular system, no accumulative effects, no metabolite toxicity, and metabolic product has no neuromuscular blocking effects, due to slow onset and unsatisfactory intubating conditions, the use of cisatracurium is limited compared with those seen with equipotent doses of other neuromuscular blocking agents. This study was undertaken to find onset time and intubating conditions with 3 × ED95 doses of atracurium versus cisatracurium. METHODS ASA grade 1 or 2 patients, (N = 220) were randomly allocated into 2 groups to receive equipotent doses of either atracurium or cisatracurium. Intubating conditions were assessed using Cooper et al scale and neuromuscular monitoring done using TOF Watch SX. Haemodynamic responses and any adverse effects were noted. RESULTS The onset time was 167.36 ± 75.41 seconds (2.78 ± 1.25 minutes) in atracurium group whereas in cisatracurium group, onset time was 249.26 ± 75.90 seconds (4.15 ± 1.26) and the difference was statistically significant with p value of < 0.001. The difference in intubating conditions between the groups was statistically insignificant. However, atracurium produced a higher incidence of clinically acceptable conditions (excellent in 94.4 %) than cisatracurium (excellent in 87.3 %). The incidence of adverse effects such as erythema, flushing and bronchospasm was greater in Atracurium group though hypotension was observed in both groups. CONCLUSIONS Onset time and intubating conditions are significantly better with equipotent doses of atracurium compared to cisatracurium. But atracurium is associated with higher incidence of adverse effects such as erythema, flushing and bronchospasm, though the potential of cisatracurium to cause anaphylactoid reactions cannot be ignored. KEYWORDS Cisatracurium, Atracurium, Muscle Relaxants, Neuromuscular Blocking Agents, Erythema, Flushing, Bronchospasm, Hypotension, Anaphylactoid Reactions

Adverse Effects of Depolarising Neuromuscular Blocking Agents

Drug Safety ◽  
1994 ◽  
Vol 10 (5) ◽  
pp. 331-349 ◽  
Author(s):  
W. Jeffrey Book ◽  
Mark Abel ◽  
James B. Eisenkraft
Keyword(s):  
Adverse Effects ◽  
Neuromuscular Blocking ◽  
Neuromuscular Blocking Agents ◽  
Blocking Agents

Adverse Effects of Nondepolarising Neuromuscular Blocking Agents

Drug Safety ◽  
1994 ◽  
Vol 10 (6) ◽  
pp. 420-438 ◽  
Author(s):  
Mark Abel ◽  
W. Jeffrey Book ◽  
James B. Eisenkraft
Keyword(s):  
Adverse Effects ◽  
Neuromuscular Blocking ◽  
Neuromuscular Blocking Agents ◽  
Blocking Agents

scholarly journals Dosing of neuromuscular blocking agents in patients with obesity: A narrative review

2021 ◽  
pp. 0310057X2096857
Author(s):  
Brian L Erstad ◽  
Jeffrey F Barletta
Keyword(s):  
Body Weight ◽  
Ideal Body Weight ◽  
Neuromuscular Blocking ◽  
Neuromuscular Blocking Agents ◽  
Patient Specific ◽  
Lean Body Weight ◽  
Short Term ◽  
Blocking Agents ◽  
Ideal Body ◽  
Size Descriptor

There is no consensus on which weight clinicians should use for weight-based dosing of neuromuscular blocking agents (NMBAs), as exemplified by differing or absent recommendations in clinical practice guidelines. The purpose of this paper is to review studies that evaluated various size descriptors for weight-based dosing of succinylcholine and non-depolarising NMBAs, and to provide recommendations for the descriptors of choice for the weight-based dosing of these agents in patients with obesity. All of the studies conducted to date involving depolarising and non-depolarising NMBAs in patients with obesity have assessed single doses or short-term infusions conducted in perioperative settings. Recognising that any final dosing regimen must take into account patient-specific considerations, the available evidence suggests that actual body weight is the size descriptor of choice for weight-based dosing of succinylcholine and that ideal body weight, or an adjusted (or lean) body weight, is the size descriptor of choice for weight-based dosing of non-depolarising NMBAs.

Fumarates: Unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine

2009 ◽  
Vol 24 (1) ◽  
pp. 50-57 ◽  
Author(s):  
Cynthia A. Lien ◽  
Peter Savard ◽  
Matthew Belmont ◽  
Hiorshi Sunaga ◽  
John J. Savarese
Keyword(s):  
Neuromuscular Blocking ◽  
Neuromuscular Blocking Agents ◽  
Blocking Agents
Sign in / Sign up

Export Citation Format

Share Document